AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE (R)) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
conference contribution
posted on 2019-11-01, 00:00authored byMark A Rosenthal, Carmen Balana, Myra E van Linde, Cyrus Sayehli, Walter M Fiedler, Martin Wermke, Christophe Massard, Ingo K Mellinghoff, Mustafa Khasraw, Agnes Ang, Erik Rasmussen, Johannes Kast, Sabine Stienen, Timothy F Cloughesy
AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE (R)) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
24th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS